MIP Search | Managing Intellectual Property

A counterfeit cure

AstraZeneca is using cutting-edge technology in a bid to keep counterfeits out of the supply chain. Emma Barraclough finds out how its new system will work

Managing IP Correspondent, March 31 2007

Patents

Too much too soon? Firms reveal AI expectations

Practitioners say it's hard to measure the extent to which AI will transform their businesses because the technology is continuously evolving

Rani Mehta, September 26 2024

Utynam's Heirs

A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam – who received the world’s first recorded patent in 1449 diary@managingip.com

Managing IP Correspondent, May 31 2011

Unpleasant surprises: combatting bad-faith filings in third countries

IP offices and courts should take a reality-driven approach to bad-faith trademark filings, argues Gregor Versondert, director and assistant general counsel at Procter & Gamble

Gregor Versondert, December 15 2020

Netaji Subhash Chandra Bose at the India Gate in New Delhi

Sponsored by Remfry & Sagar

Guarding the invisible: trade secrets law in India

Mohini V of Remfry & Sagar outlines how Indian courts and policymakers are shaping trade secret protection through case law, equitable principles, and proposed legislation, as businesses face rising digital threats and cross-border confidentiality challenges

Mohini V, October 16 2025

Moves: Adams merges with Bowman IP

In South Africa, Adams & Adams has merged with corporate rival Bowman Gilfillan's IP practice. Fifty-nine new staff including 19 lawyers joined the IP specialist's 60-lawyer practice on March 1. Five Bowman Gilfillan partners Eugene Honey (head of the IP practice), Darren Olivier, Marius Gerber, Johnny Fiandeiro and Debbie Marriott will retain the same position at Adam & Adams. Partner Marius Haman moved to an in-house role at Microsoft.

Managing IP Correspondent, March 27 2012

Andean IP protection overhauled

The rules governing intellectual property in the five countries of the Andean Pact have been revised. Cecilia Falconi examines the key aspects of the new legislation.

Managing IP Correspondent, December 01 2000

A guide to supplementary protection

Because pharmaceutical companies perform time-consuming clinical trials before receiving a marketing authorisation (MA) to put a product on the market, the protection offered by pharmaceutical product patents is often reduced by five to 10 years. This reduces the benefits from an IP monopoly.

Managing IP Correspondent, February 01 2010

Develop your enforcement strategy in Latin America

Latin America represents an increasingly attractive investment option for many IP owners. But how should they protect their rights there? Managing IP, Olivares & Cia, Baker & McKenzie Latin America and Obligado & Cia hosted a roundtable to discuss the issue

Managing IP Correspondent, March 01 2008

Mexico off to a good start with Madrid

Mexico has not been a member of the Madrid Protocol for long but Miguel Angel Margáin, director general of the Instituto Mexicano de la Propiedad Industrial (IMPI), the country’s patent and trademark office, believes it been a big success so far.

May 12 2014

Search results for